Differences in five year survival after cancer diagnosis between HIV clinic enrollees and the general US population.
A total of 236 PWH with cancer diagnosed between 1997 and 2014 in the Johns Hopkins HIV Clinical Cohort (JHHCC) were compared to a sample from NCI's Surveillance, Epidemiology and End Results (SEER) Program, presumed to be HIV negative. Using G-computation with random survival forest methods, we estimated 5-year restricted mean survival time differences by HIV status. Sensitivity analyses were performed among non-AIDS defining cancers, males, females, and stratifying PWH by CD4 ≤200 or >200 cells/mm3 at cancer diagnosis. PWH with CD4 ≤200 had decreased survival compared to those in SEER (-7 months; 95% CI=-13, -2). Women with HIV and CD4 ≤200 at cancer diagnosis had lower survival than SEER women (-10 months; 95% CI=-18, -2). In the total population, there was no significant difference in 5-year restricted mean survival time; however, women with HIV and low CD4 had higher mortality despite accounting for stage at diagnosis and first course of cancer treatment.